Sandoz Confirms Launch Of Humira Rival In Canada
Introduction Of Hyrimoz Comes As Other Adalimumab Biosimilars Expected
Executive Summary
Sandoz has confirmed the launch of its Hyrimoz biosimilar rival to Humira in Canada, with other biosimilars firms having also set their sights on a mid-February launch.
You may also be interested in...
Enoxaparin Biosimilar Makes It Six For Sandoz Canada
Sandoz Canada has taken another “important step as we pursue our ambition to become the leading biosimilars and generics company” with the launch of biosimilar enoxaparin.
Sandoz Aims To Be ‘First In And Last Out’ In North America
Sandoz is determined to be “first in and last out” on key product opportunities, while also seeking to strengthen its pipeline through deals and partnerships, the company’s new North America head, Keren Haruvi, tells Generics Bulletin in an exclusive interview.
Five Competitors Confirmed On Canadian Adalimumab
Multiple competitors have now confirmed the launch of Canadian biosimilar versions of the world’s biggest-selling drug, Humira.